

Elisa Vigna

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2292608/elisa-vigna-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

50
papers

4,517
citations

26
h-index

51
g-index

51
ext. papers

4,769
ext. citations

8.9
avg, IF

4.6
L-index

#	Paper	IF	Citations
50	hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of SMET-addicted Scancers.. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022 , 41, 112	12.8	0
49	Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor.. <i>Frontiers in Immunology</i> , 2021 , 12, 775151	8.4	0
48	HGF/MET Axis Induces Tumor Secretion of Tenascin-C and Promotes Stromal Rewiring in Pancreatic Cancer. <i>Cancers</i> , 2021 , 13,	6.6	4
47	A receptor-antibody hybrid hampering MET-driven metastatic spread. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021 , 40, 32	12.8	2
46	Molecular Engineering Strategies Tailoring the Apoptotic Response to a MET Therapeutic Antibody. <i>Cancers</i> , 2020 , 12,	6.6	2
45	CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes. <i>Clinical Cancer Research</i> , 2020 , 26, 6321-6334	12.9	5
44	Met inhibition revokes IFN γ induction of PD-1 ligands in MET-amplified tumours. <i>British Journal of Cancer</i> , 2019 , 120, 527-536	8.7	26
43	CD44v6 as innovative sarcoma target for CAR-redirectioned CIK cells. <i>Oncolmmunology</i> , 2018 , 7, e1423167	7.2	21
42	Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategy. <i>International Journal of Cancer</i> , 2018 , 143, 1774-1785	7.5	8
41	MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	14
40	Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib. <i>Journal of Molecular and Cellular Cardiology</i> , 2016 , 93, 84-97	5.8	6
39	Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody. <i>Cancer Research</i> , 2016 , 76, 5019-29	10.1	16
38	Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody. <i>Molecular Oncology</i> , 2016 , 10, 938-48	7.9	10
37	Targeting the oncogenic Met receptor by antibodies and gene therapy. <i>Oncogene</i> , 2015 , 34, 1883-9	9.2	33
36	Anti-Differentiation Effect of Oncogenic Met Receptor in Terminally-Differentiated Myotubes. <i>Biomedicines</i> , 2015 , 3, 124-137	4.8	1
35	Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30. <i>Molecular Oncology</i> , 2015 , 9, 1760-72	7.9	15
34	Quiescent neuronal progenitors are activated in the juvenile guinea pig lateral striatum and give rise to transient neurons. <i>Development (Cambridge)</i> , 2014 , 141, 4065-75	6.6	26

33	Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor. <i>Journal of Molecular Medicine</i> , 2014 , 92, 65-76	5.5	8
32	Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. <i>Clinical Cancer Research</i> , 2013 , 19, 2381-92	12.9	139
31	A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 2459-71	6.1	25
30	Human cord blood CD34+ progenitor cells acquire functional cardiac properties through a cell fusion process. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011 , 300, H1875-84	5.2	24
29	Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. <i>Journal of Biological Chemistry</i> , 2010 , 285, 36149-57	5.4	67
28	T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR. <i>Human Gene Therapy</i> , 2009 , 20, 1576-88	4.8	33
27	The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. <i>Journal of Clinical Investigation</i> , 2009 , 119, 2366-78	15.9	200
26	"Active" cancer immunotherapy by anti-Met antibody gene transfer. <i>Cancer Research</i> , 2008 , 68, 9176-83	10.1	32
25	Functional properties of cells obtained from human cord blood CD34+ stem cells and mouse cardiac myocytes in coculture. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008 , 294, H1541-9	5.2	12
24	Identification of myocardial and vascular precursor cells in human and mouse epicardium. <i>Circulation Research</i> , 2007 , 101, 1255-65	15.7	193
23	MET overexpression turns human primary osteoblasts into osteosarcomas. <i>Cancer Research</i> , 2006 , 66, 4750-7	10.1	106
22	Retroviral vectors containing Tet-controlled bidirectional transcription units for simultaneous regulation of two gene activities. <i>Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research</i> , 2006 , 2, 107-18	2.5	13
21	Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. <i>Nature Biotechnology</i> , 2005 , 23, 108-16	44.5	254
20	Efficient Tet-dependent expression of human factor IX in vivo by a new self-regulating lentiviral vector. <i>Molecular Therapy</i> , 2005 , 11, 763-75	11.7	56
19	Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors. <i>Molecular Therapy</i> , 2002 , 5, 252-61	11.7	132
18	Hepatocyte growth factor is a regulator of monocyte-macrophage function. <i>Journal of Immunology</i> , 2001 , 166, 1241-7	5.3	102
17	Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. <i>Journal of Gene Medicine</i> , 2000 , 2, 308-16	3.5	285
16	Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET. <i>Oncogene</i> , 1999 , 18, 4275-81	9.2	52

15	Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor Met. <i>Biochemical Journal</i> , 1998 , 336 (Pt 1), 235-9	3.8	28
14	Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. <i>Journal of Biological Chemistry</i> , 1995 , 270, 603-11	5.4	201
13	Structure and functions of the HGF receptor (c-Met) 1995 , 51-70		1
12	A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992 , 89, 11574-8	11.5	201
11	Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor.. <i>EMBO Journal</i> , 1992 , 11, 4825-4833	13	393
10	Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. <i>EMBO Journal</i> , 1992 , 11, 4825-33	13	134
9	The Receptor for the Hepatocyte Growth Factor-Scatter Factor: Ligand-Dependent and Phosphorylation-Dependent Regulation of Kinase Activity 1992 , 301-310		
8	The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation. <i>Molecular and Cellular Biology</i> , 1991 , 11, 1793-803	4.8	179
7	Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor.. <i>EMBO Journal</i> , 1991 , 10, 2867-2878	13	486
6	Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase. <i>Journal of Biological Chemistry</i> , 1991 , 266, 19558-64	5.4	88
5	Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. <i>Oncogene</i> , 1991 , 6, 501-4	9.2	523
4	Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. <i>EMBO Journal</i> , 1991 , 10, 2867-78	13	193
3	Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase.. <i>Journal of Biological Chemistry</i> , 1991 , 266, 19558-19564	5.4	105
2	The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation. <i>Molecular and Cellular Biology</i> , 1991 , 11, 1793-1803	4.8	63
1	Lentiviral Vectors for Cancer Gene Therapy83-94		